24 Ces Urol 2022; 26(1): 13–28 PŘEHLEDOVÉ ČLÁNKY 36. Sharma P, Zargar‑Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2015; 33(8): 339.e17–339.e23. doi:10.1016/j.urolonc.2015. 01. 011. 37. Psutka SP. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer. 2020; 126(17): 3912–3915. doi:10.1002/cncr.32993. 38. Ito H, Shioi K, Murakami T, et al. C‑reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer. 2012; 12(1): 337. doi:10.1186/1471-2407-12-337. 39. Sakai I, Miyake H, Hinata N, Fujisawa M. Improved survival in patients with metastatic renal cell carci‑ noma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol. 2014; 19(4): 674–678. doi:10.1007/s10147-013-0612-z. 40. Baum YS, Patil D, Huang JH, et al. Elevated preoperative neutrophil‑to‑lymphocyte ratio may be asso‑ ciated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Asian J Urol. 2016; 3(1): 20–25. doi:10.1016/j.ajur.2015. 09. 004. 41. Peyton CC, Abel EJ, Chipollini J, et al. The Value of Neutrophil to Lymphocyte Ratio in Patients Under‑ going Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020; 6(1): 104–111. doi:10.1016/j. euf.2018. 08. 023. 42. Day D, Kanjanapan Y, Kwan E, et al. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil‑to‑lymphocyte ratio in patients with metastatic renal cell carcinoma. Intern Med J. 2016; 46(11): 1291–1297. doi:10.1111/imj.13202. 43. Gu L, Ma X, Xie Y, et al. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognos‑ tic Factor in Metastatic Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2017; 15(3): e369–e377. doi:10.1016/j.clgc.2016. 12. 001. 44. Margulis V, Shariat SF, Rapoport Y, et al. Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Eur Urol. 2013; 63(5): 947–952. doi:10.1016/j.eururo.2012. 11. 040. 45. Corcoran AT, Kaffenberger SD, Clark PE, et al. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int. 2015; 116(3): 351–357. doi:10.1111/bju.12897. 46. Lee H, Kim YJ, Hwang EC, et al. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto‑reductive nephrectomy. BMC Cancer. 2017; 17(1): 364. doi:10.1186/s12885-017-3322-5. 47. Ishihara H, Kondo T, Yoshida K, et al. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcino‑ ma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. Clin Genitourin Cancer. 2017; 15(5): 598–604. doi:10.1016/j.clgc.2017. 04. 011. 48. Laukhtina E, Pradere B, D`Andrea D, et al. Association of preoperative serum De Ritis ratio with onco‑ logical outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2020; 38(12): 936.e7–936.e14. doi:10.1016/j.urolonc.2020. 08. 013. 49. Culp SH, Schellhammer PF, Williams MB. Might Men Diagnosed with Metastatic Prostate Cancer Be‑ nefit fromDefinitive Treatment of the Primary Tumor? A SEER‑Based Study. Eur Urol. 2014; 65(6): 1058–1066. doi:10.1016/j.eururo.2013. 11. 012. 50. McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrec‑ tomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020; 126(17): 3950–3960. doi:10.1002/cncr.32991.
RkJQdWJsaXNoZXIy NDA4Mjc=